

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number
WO 03/013578 A1

(51) International Patent Classification⁷: **A61K 38/17**,
45/00, G01N 33/50, A61P 03/00

(21) International Application Number: PCT/IB02/03344

(22) International Filing Date: 5 August 2002 (05.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/310,784 7 August 2001 (07.08.2001) US
60/310,731 7 August 2001 (07.08.2001) US
60/333,946 19 November 2001 (19.11.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): GENSET S.A. [FR/FR]; Intellectual Property Department, 24, rue Royale, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LUCAS, John [US/US]; 339 The Valley Road, Concord, MA 01742 (US). DIALYNAS, Deno [US/US]; 3425 Lebon Drive, #813, San Diego, CA 92122 (US). BRIGGS, Kristen [US/US]; 2454 Mango Way, Del Mar, CA 92014 (US).

(74) Common Representative: GENSET S.A.; c/o De Luca, Giampiero, Serono International S.A., Intellectual Property, 12, Chemin des Aulx, 1228 Plan-les-Ouates (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF METABOLIC DISORDERS WITH OMOXIN AGONISTS AND ANTAGONISTS

(57) Abstract: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of OMOXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.



WO 03/013578 A1

OMOXIN AGONISTS AND ANTAGONISTS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS.

Field of the Invention

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and maintaining weight loss and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. The present invention additionally relates elsewhere to the field of metabolic research, in particular the discovery of compounds effective for increasing body mass and useful for treating disorders associated with excessive weight loss. Applicant reserves the right to exclude any of the aforesaid obesity-related diseases or disorders. The disorders associated with excessive weight loss and envisioned to be treated by the methods of the invention include, but are not limited to, cachexia, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, and anorexia. Applicant reserves the right to exclude any of the aforesaid disorders associated with excessive weight loss.

In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of OMOXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

Background of the Invention

The following discussion is intended to facilitate the understanding of the invention, but is not intended nor admitted to be prior art to the invention.

Obesity is a public health problem that is serious, widespread, and increasing. In the United States, 20 percent of the population is obese; in Europe, a slightly lower percentage is obese (Friedman (2000) Nature 404:632-634). Obesity is associated with increased risk of hypertension, cardiovascular disease, diabetes, and cancer as well as respiratory complications and osteoarthritis (Kopelman (2000) Nature 404:635-643). Even modest weight loss ameliorates these associated conditions.

Recently it was shown that particular carboxyl-terminal fragments of the full-length ACRP30 (mouse) and APM1 (human) polypeptides have unexpected effects *in vitro* and *in vivo*, including utility for weight reduction, prevention of weight gain, and control of blood glucose levels (Fruebis et al (2001) Proc Natl Acad Sci USA 98:2005-10). The effects of ACRP30 fragment administration in mammals also include reduction of elevated free fatty acid levels including elevated free fatty acid levels caused by administration of epinephrine, *i.v.* injection of "intralipid", or administration of a high fat test meal, as well as increased fatty acid oxidation in muscle cells, and weight reduction in mammals consuming a normal or high fat/high sucrose diet.

Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent specification referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.

5

Summary of the Invention

APM1 belongs to an expanding family of related secreted polypeptides that includes among others C2P, ZADJ-2 and ZADJ-7. These polypeptides have in common the structure: signal peptide, N-terminally disposed unique region, collagen-like region, and globular C-terminal C1q homology domain. APM1, C2P, ZADJ-2 and ZADJ-7 further share an NGLXXD amino acid motif
10 C-terminally disposed within the globular domain within a loop implicated in receptor binding, wherein said receptor is OMOXIN. Fragments of APM1, C2P, ZADJ-2 and ZADJ-7 polypeptide comprising the globular domain are herein referred to as gAPM1, gC2P, gZADJ-2 and gZADJ-7. It is further taken to be understood herein that LIGAND refers to a composition consisting essentially of or consisting of *in vitro* or *in vivo* self-assembling homotrimer comprised of gAPM1, gC2P,
15 gZADJ-2, or gZADJ-7 polypeptide fragment.

OMOXIN is a member of the Tumor Necrosis Factor Receptor Super Family (TNFRSF) and is a Type I transmembrane protein. The instant invention is based on OMOXIN as receptor for LIGAND that mediates effects, including utility for weight reduction, maintenance of weight loss, prevention of weight gain, increased insulin sensitivity, and control of blood glucose levels in
20 humans and other mammals. These effects in mammals of OMOXIN engagement by LIGAND also include reduction of elevated free fatty acid levels including elevated free fatty acid levels including elevated free fatty acid levels caused by administration of epinephrine, *i.v.* injection of "intralipid", or administration of a high fat test meal, as well as increased fatty acid oxidation in muscle cells, and weight reduction in mammals consuming a normal or high fat/high sucrose diet. More specifically,
25 the present invention is directed to OMOXIN to which LIGAND binds and through which LIGAND mediates said effects.

In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of OMOXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity, as well as to pharmaceutical and
30 physiologically acceptable compositions comprising said OMOXIN AGONISTS or ANTAGONISTS and methods of administering said pharmaceutical and physiologically acceptable compositions in order to increase or reduce body weight, maintain weight loss, or to treat obesity-related diseases and disorders. Assays for identifying AGONISTS and ANTAGONISTS of obesity-related activity are also part of the invention.

Preferably said OMOXIN AGONIST or ANTAGONIST is a compound selected from the group consisting of polypeptide, polypeptide fragment, peptide, proein, antibody, carbohydrate, lipid, small molecular weight organic compound and small molecular weight inorganic compound.

Preferably said OMOXIN AGONIST or ANTAGONIST is a compound that selectively
5 binds to the extracellular domain of OMOXIN.

In other embodiment, said OMOXIN AGONIST or ANTAGONIST is a compound that selectively binds to the intracellular domain of a polypeptide comprising the extracellular domain of OMOXIN.

The present invention also provides a method of assaying test compounds to identify a test
10 compound that binds to OMOXIN polypeptide. The method comprises contacting OMOXIN polypeptide with a test compound and to determine the extent of binding of the test compound to said OMOXIN polypeptide. The method further comprises determining whether such test compounds are AGONISTS or ANTAGONISTS of OMOXIN polypeptide. The present invention further provides a method of testing the impact of molecules on the expression of OMOXIN
15 polypeptide or on the activity of OMOXIN polypeptide.

The present invention also relates to diagnostic methods of identifying individuals or non-human animals having elevated or reduced levels of OMOXIN products, which individuals are likely to benefit from therapies to suppress or enhance OMOXIN expression, respectively, and to methods of identifying individuals or non-human animals at increased risk for developing, or present
20 state of having, certain diseases/disorders associated with OMOXIN abnormal expression or biological activity.

The present invention provides for methods of identifying AGONISTS of OMOXIN polypeptide biological activity comprising contacting a small molecule compound with OMOXIN polypeptides and measuring OMOXIN polypeptide biological activity in the presence and absence
25 of these small molecules. The present invention further provides for methods of identifying ANTAGONISTS of OMOXIN polypeptide biological activity comprising contacting a small molecule compound with OMOXIN polypeptides and measuring OMOXIN polypeptide biological activity in the presence and absence of these small molecules. These small molecules can be a naturally occurring medicinal compound or derived from combinatorial chemical libraries.

30 The present invention also relates to pharmaceutical or physiologically acceptable compositions comprising, an active agent, including AGONIST or ANTAGONIST of the present invention.

In a first aspect, the invention is directed to OMOXIN AGONISTS, wherein said AGONIST is an antibody that specifically binds OMOXIN, a compound excluding said OMOXIN antibody

(e.g., small organic or inorganic compound, protein, peptide, carbohydrate, lipid), or a LIGAND polypeptide or fragment thereof.

In a further preferred embodiment, the invention is directed to a OMOXIN AGONIST, wherein said AGONIST is an antibody that specifically binds OMOXIN. More preferably the invention is directed to said OMOXIN antibody, wherein said OMOXIN antibody binds OMOXIN and manifests LIGAND activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein.

In a further preferred embodiment, the invention is directed to a OMOXIN AGONIST, wherein said AGONIST is a compound excluding said OMOXIN antibody. More preferably the invention is directed to said compound, wherein said compound binds OMOXIN and manifests LIGAND activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein. Further more preferably the invention is directed to said compound, wherein said compound manifests LIGAND activity exclusive of binding to OMOXIN, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein. Further more preferably the invention is directed to said compound, wherein said compound increases OMOXIN expression.

In a further preferred embodiment, the invention is directed to a OMOXIN AGONIST that selectively binds to a polypeptide comprising the extracellular domain of OMOXIN.

In a further preferred embodiment, the invention is directed to a OMOXIN AGONIST, wherein said AGONIST is LIGAND, and wherein it is understood that LIGAND refers to a composition consisting essentially of or consisting of *in vitro* or *in vivo* self-assembling homotrimer comprised of gAPM1, gC2P, gZADJ-2, or gZADJ-7 polypeptide fragment. More preferably the invention is directed to said LIGAND, wherein said LIGAND binds OMOXIN and elicits biological activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein. More preferably the invention is directed to said LIGAND, wherein said LIGAND induces, enhances, or potentiates said biological activity exclusive of binding to OMOXIN. In preferred embodiment, said homotrimer is comprised of preferred gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment.

APM1. Preferred gAPM1 polypeptide fragment is selected from amino acids **18-244**, **34-244**, 49-244, 56-244, 59-244, 66-244, 69-244, 78-244, 85-244, 93-244, 101-244, 102-244, 103-244, 104-244, 107-244, **110-244** or **113-244**, wherein said numbering of said amino acids within APM1 amino acid sequence is understood to be taken from said APM1 amino acid sequence presented in Table 2. Less preferred gAPM1 fragments are indicated in bold.

C2P. Preferred gC2P polypeptide fragment is selected from amino acids **20-333**, 25-333, 43-333, 45-333, 46-333, 50-333, 53-333, 61-333, 67-333, 74-333, 75-333, 77-333, 81-333, 82-333,

86-333, 89-333, 95-333, 100-333, 104-333, 113-333, 116-333, 125-333, 128-333, 140-333, 160-333, 164-333, 179-333, 182-333, 185-333, 188-333, 191-333, 193-333, or **202-333**, wherein said numbering of said amino acids within C2P amino acid sequence is understood to be taken from said C2P amino acid sequence presented in Table 2. Less preferred gC2P fragments are indicated in
5 bold.

ZADJ-2. Preferred gZADJ-2 polypeptide fragment is selected from amino acids **16-285**, **25-285**, **26-285**, **29-285**, **30-285**, 91-285, 93-285, 97-285, 98-285, 99-285, 105-285, 109-285, 112-285, 120-285, 126-285, 127-285, 130-285, 132-285, 133-285, 134-285, or **150-285**, wherein said numbering of said amino acids within ZADJ-2 amino acid sequence is understood to be taken from
10 said ZADJ-2 amino acid sequence presented in Table 2. Less preferred gZADJ-2 fragments are indicated in bold.

ZADJ-7. Preferred gZADJ-7 polypeptide fragment is selected from amino acids **31-303**, **39-303**, 78-303, 81-303, 84-303, 85-303, 88-303, 91-303, 97-303, 99-303, 109-303, 117-303, 118-303, 127-303, 139-303, 142-303, **155-303**, or **162-303**, wherein said numbering of said amino acids
15 within ZADJ-7 amino acid sequence is understood to be taken from said ZADJ-7 amino acid sequence presented in Table 2. Less preferred gZADJ-7 fragments are indicated in bold.

More preferred LIGAND is APM1.

In a further preferred embodiment, said AGONIST is able to lower circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

20 Further preferred AGONISTS are those that significantly stimulate muscle lipid or free fatty acid oxidation as compared to untreated cells. Further preferred AGONISTS are those that cause C2C12 cells differentiated in the presence of said AGONISTS to undergo at least 10%, 20%, 30%, 35%, or 40% more oleate oxidation as compared to untreated cells.

Further preferred AGONISTS are those that increase by at least 10%, 20%, 30%, 35%, or
25 40% leptin uptake in a liver cell line [preferably BPRCL mouse liver cells (ATCC CRL-2217)] as compared to untreated cells.

Further preferred AGONISTS are those that significantly reduce the postprandial increase in plasma free fatty acids or triglycerides, particularly following a high fat meal.

Further preferred AGONISTS are those that significantly reduce or eliminate ketone body
30 production, particularly following a high fat meal.

Further preferred AGONISTS are those that increase glucose uptake in skeletal muscle cells.

Further preferred AGONISTS are those that increase glucose uptake in adipose cells.

Further preferred AGONISTS are those that increase glucose uptake in neuronal cells.

Further preferred AGONISTS are those that increase glucose uptake in red blood cells.

Further preferred AGONISTS are those that increase glucose uptake in the brain.

Further preferred AGONISTS are those that significantly reduce the postprandial increase in plasma glucose following a meal, particularly a high carbohydrate meal.

Further preferred AGONISTS are those that significantly prevent the postprandial increase
5 in plasma glucose following a meal, particularly a high fat or a high carbohydrate meal.

Further preferred AGONISTS are those that improve insulin sensitivity.

Further preferred said AGONISTS are those that decrease body mass, wherein said decrease in body mass is comprised of a change in mass of the subcutaneous adipose tissue.

Further preferred said AGONISTS are those that decrease body mass, wherein said decrease
10 in body mass is comprised of a change in mass of the visceral (omental) adipose tissue.

In a second aspect, the invention features a pharmaceutical or physiologically acceptable composition comprising, consisting essentially of, or consisting of, said AGONIST described in the first aspect and, alternatively, a pharmaceutical or physiologically acceptable diluent.

In a third aspect, the invention features a method of reducing body mass comprising
15 providing or administering to individuals in need of reducing body mass said pharmaceutical or physiologically acceptable composition described in the second aspect.

In a fourth aspect, the invention features a method of preventing or treating an obesity-related disease or disorder comprising providing or administering to an individual in need of such treatment said pharmaceutical or physiologically acceptable composition described in the second
20 aspect. Preferably, said obesity-related disease or disorder is selected from the group consisting of obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes). Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular lesions,
25 retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by said OMOXIN AGONIST of the invention include hyperlipidemia and hyperuricemia. In preferred embodiments, said individual is a mammal, preferably a human.

In related aspects, embodiments of the present invention includes methods of causing or
30 inducing a desired biological response in an individual comprising the steps of: providing or administering to an individual a composition comprising AGONIST, wherein said biological response is selected from the group consisting of:

- (a) lowering circulating (either blood, serum, or plasma) levels (concentration) of free fatty acids;

<221> VARIANT

<222> 330

<223> Polymorphic amino acid Thr or Ala

<221> VARIANT

<222> 405

<223> Polymorphic amino acid Val or Ile

<400> 4

```

Met Ala Leu Lys Val Leu Leu Glu Gln Glu Lys Thr Phe Phe Thr Leu
 1          5          10          15
Leu Val Leu Leu Gly Tyr Leu Ser Cys Lys Val Thr Cys Glu Ser Gly
          20          25          30
Asp Cys Arg Gln Gln Glu Phe Arg Asp Arg Ser Gly Asn Cys Val Pro
          35          40          45
Cys Asn Gln Cys Gly Pro Gly Met Glu Leu Ser Lys Glu Cys Gly Phe
          50          55          60
Gly Tyr Gly Glu Asp Ala Gln Cys Val Thr Cys Arg Leu His Arg Phe
          65          70          75          80
Lys Glu Asp Trp Gly Phe Gln Lys Cys Lys Pro Cys Leu Asp Cys Ala
          85          90          95
Val Val Asn Arg Phe Gln Lys Ala Asn Cys Ser Ala Thr Ser Asp Ala
          100          105          110
Ile Cys Gly Asp Cys Leu Pro Gly Phe Tyr Arg Lys Thr Lys Leu Val
          115          120          125
Gly Phe Gln Asp Met Glu Cys Val Pro Cys Gly Asp Pro Pro Pro Pro
          130          135          140
Tyr Glu Pro His Cys Ala Ser Lys Val Asn Leu Val Lys Ile Ala Ser
          145          150          155          160
Thr Ala Ser Ser Pro Arg Asp Thr Ala Leu Ala Ala Val Ile Cys Ser
          165          170          175
Ala Leu Ala Thr Val Leu Leu Ala Leu Leu Ile Leu Cys Val Ile Tyr
          180          185          190
Cys Lys Arg Gln Phe Met Glu Lys Lys Pro Ser Trp Ser Leu Arg Ser
          195          200          205
Gln Asp Ile Gln Tyr Asn Gly Ser Glu Leu Ser Cys Phe Asp Arg Pro
          210          215          220
Gln Leu His Glu Tyr Ala His Arg Ala Cys Cys Gln Cys Arg Arg Asp
          225          230          235          240
Ser Val Gln Thr Cys Gly Pro Val Arg Leu Leu Pro Ser Met Cys Cys
          245          250          255
Glu Glu Ala Cys Ser Pro Asn Pro Ala Thr Leu Gly Cys Gly Val His
          260          265          270
Ser Ala Ala Ser Leu Gln Ala Arg Asn Ala Gly Pro Ala Gly Glu Met
          275          280          285
Val Pro Thr Phe Phe Gly Ser Leu Thr Gln Ser Ile Cys Gly Glu Phe
          290          295          300
Ser Asp Ala Trp Pro Leu Met Gln Asn Pro Met Gly Gly Asp Asn Ile
          305          310          315          320
Ser Phe Cys Asp Ser Tyr Pro Glu Leu Thr Gly Glu Asp Ile His Ser
          325          330          335
Leu Asn Pro Glu Leu Glu Ser Ser Thr Ser Leu Asp Ser Asn Ser Ser
          340          345          350
Gln Asp Leu Val Gly Gly Ala Val Pro Val Gln Ser His Ser Glu Asn
          355          360          365
Phe Thr Ala Ala Thr Asp Leu Ser Arg Tyr Asn Asn Thr Leu Val Glu
          370          375          380
Ser Ala Ser Thr Gln Asp Ala Leu Thr Met Arg Ser Gln Leu Asp Gln
          385          390          395          400
Glu Ser Gly Ala Val Ile His Pro Ala Thr Gln Thr Ser Leu Gln Glu
          405          410          415
Ala

```

<210> 5
 <211> 987
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(987)

<400> 5
 atg gct tta aaa gtg cta cta gaa caa gag aaa acg ttt ttc act ctt 48
 Met Ala Leu Lys Val Leu Leu Glu Gln Glu Lys Thr Phe Phe Thr Leu
 1 5 10 15

tta gta tta cta ggc tat ttg tca tgt aaa gtg act tgt gaa tca gga 96
 Leu Val Leu Leu Gly Tyr Leu Ser Cys Lys Val Thr Cys Glu Ser Gly
 20 25 30

gac tgt aga cag caa gaa ttc agg gat cgg tct gga aac tgt gtt ccc 144
 Asp Cys Arg Gln Gln Glu Phe Arg Asp Arg Ser Gly Asn Cys Val Pro
 35 40 45

tgc aac cag tgt ggg cca ggc atg gag ttg tct aag gaa tgt ggc ttc 192
 Cys Asn Gln Cys Gly Pro Gly Met Glu Leu Ser Lys Glu Cys Gly Phe
 50 55 60

ggc tat ggg gag gat gca cag tgt gtg acg tgc cgg ctg cac agg ttc 240
 Gly Tyr Gly Glu Asp Ala Gln Cys Val Thr Cys Arg Leu His Arg Phe
 65 70 75 80

aag gag gac tgg ggc ttc cag aaa tgc aag ccc tgt ctg gac tgc gca 288
 Lys Glu Asp Trp Gly Phe Gln Lys Cys Lys Pro Cys Leu Asp Cys Ala
 85 90 95

gtg gtg aac cgc ttt cag aag gca aat tgt tca gcc acc agt gat gcc 336
 Val Val Asn Arg Phe Gln Lys Ala Asn Cys Ser Ala Thr Ser Asp Ala
 100 105 110

atc tgc ggg gac tgc ttg cca gga ttt tat agg aag acg aaa ctt gtc 384
 Ile Cys Gly Asp Cys Leu Pro Gly Phe Tyr Arg Lys Thr Lys Leu Val
 115 120 125

ggc ttt caa gac atg gag tgt gtg cct tgt gga gac cct cct cct cct 432
 Gly Phe Gln Asp Met Glu Cys Val Pro Cys Gly Asp Pro Pro Pro Pro
 130 135 140

tac gaa ccg cac tgt gcc agc aag gtc aac ctc gtg aag atc gcg tcc 480
 Tyr Glu Pro His Cys Ala Ser Lys Val Asn Leu Val Lys Ile Ala Ser
 145 150 155 160

acg gcc tcc agc cca cgg gac acg gcg ctg gct gcc gtt atc tgc agc 528
 Thr Ala Ser Ser Pro Arg Asp Thr Ala Leu Ala Ala Val Ile Cys Ser
 165 170 175

gct ctg gcc acc gtc ctg ctg gcc ctg ctc atc ctc tgt gtc atc tat 576
 Ala Leu Ala Thr Val Leu Leu Ala Leu Leu Ile Leu Cys Val Ile Tyr
 180 185 190

tgt aag aga cag ttt atg gag aag aaa ccc agc tgg tct ctg cgg tcg 624
 Cys Lys Arg Gln Phe Met Glu Lys Lys Pro Ser Trp Ser Leu Arg Ser
 195 200 205

cag gac att cag tac aac ggc tct gag ctg tcg tgt ttt gac aga cct 672
 Gln Asp Ile Gln Tyr Asn Gly Ser Glu Leu Ser Cys Phe Asp Arg Pro
 210 215 220

 cag ctc cac gaa tat gcc cac aga gcc tgc tgc cag tgc cgc cgt gac 720
 Gln Leu His Glu Tyr Ala His Arg Ala Cys Cys Gln Cys Arg Arg Asp
 225 230 235 240

 tca gtg cag acc tgc ggg ccg gtg cgc ttg ctc cca tcc atg tgc tgt 768
 Ser Val Gln Thr Cys Gly Pro Val Arg Leu Leu Pro Ser Met Cys Cys
 245 250 255

 gag gag gcc tgc agc ccc aac ccg gcg act ctt ggt tgt ggg gtg cat 816
 Glu Glu Ala Cys Ser Pro Asn Pro Ala Thr Leu Gly Cys Gly Val His
 260 265 270

 tct gca gcc agt ctt cag gca agg aag ctt aaa gaa cct gct tct ttc 864
 Ser Ala Ala Ser Leu Gln Ala Arg Lys Leu Lys Glu Pro Ala Ser Phe
 275 280 285

 tgc agt aga agc gtg tgc tgg aac cca aag agt act cct ttg tta ggc 912
 Cys Ser Arg Ser Val Cys Trp Asn Pro Lys Ser Thr Pro Leu Leu Gly
 290 295 300

 tta tgg act gag cag tct gga cct tgc atg gct tct ggg gca aaa ata 960
 Leu Trp Thr Glu Gln Ser Gly Pro Cys Met Ala Ser Gly Ala Lys Ile
 305 310 315 320

 aat ctg aac caa act gac ggc att tga 987
 Asn Leu Asn Gln Thr Asp Gly Ile *
 325

<210> 6

<211> 328

<212> PRT

<213> Homo sapiens

<400> 6

Met Ala Leu Lys Val Leu Leu Glu Gln Glu Lys Thr Phe Phe Thr Leu
 1 5 10 15
 Leu Val Leu Leu Gly Tyr Leu Ser Cys Lys Val Thr Cys Glu Ser Gly
 20 25 30
 Asp Cys Arg Gln Gln Glu Phe Arg Asp Arg Ser Gly Asn Cys Val Pro
 35 40 45
 Cys Asn Gln Cys Gly Pro Gly Met Glu Leu Ser Lys Glu Cys Gly Phe
 50 55 60
 Gly Tyr Gly Glu Asp Ala Gln Cys Val Thr Cys Arg Leu His Arg Phe
 65 70 75 80
 Lys Glu Asp Trp Gly Phe Gln Lys Cys Lys Pro Cys Leu Asp Cys Ala
 85 90 95
 Val Val Asn Arg Phe Gln Lys Ala Asn Cys Ser Ala Thr Ser Asp Ala
 100 105 110
 Ile Cys Gly Asp Cys Leu Pro Gly Phe Tyr Arg Lys Thr Lys Leu Val
 115 120 125
 Gly Phe Gln Asp Met Glu Cys Val Pro Cys Gly Asp Pro Pro Pro Pro
 130 135 140
 Tyr Glu Pro His Cys Ala Ser Lys Val Asn Leu Val Lys Ile Ala Ser
 145 150 155 160
 Thr Ala Ser Ser Pro Arg Asp Thr Ala Leu Ala Ala Val Ile Cys Ser
 165 170 175
 Ala Leu Ala Thr Val Leu Leu Ala Leu Leu Ile Leu Cys Val Ile Tyr

[illegible]

```
<210> 7
<211> 150
<212> PRT
<213> Homo sapiens
```

[illegible]

In an eleventh aspect, AGONIST of the invention is used in methods of treating insulin resistance comprising providing to an individual said pharmaceutical or physiologically acceptable composition described in the second aspect, or AGONIST described in the first aspect.

In a preferred aspect of the methods above and disclosed herein, the amount of AGONIST
5 administered to an individual is sufficient to bring levels of OMOXIN activation to their normal levels (levels in individuals without obesity-related disease or disorder). "Normal levels" of OMOXIN activation may be followed using surrogate markers including circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

In a twelfth aspect, the invention is directed to a OMOXIN ANTAGONIST, wherein said
10 ANTAGONIST is a soluble fragment of OMOXIN polypeptide, an antibody that specifically binds OMOXIN, a compound excluding said soluble fragment of OMOXIN polypeptide and said OMOXIN antibody (e.g., small molecular weight organic or inorganic compound, protein, peptide, carbohydrate, lipid), or a variant or fragment of LIGAND polypeptide.

In a further preferred embodiment, the invention is directed to a OMOXIN ANTAGONIST,
15 wherein said ANTAGONIST is a soluble fragment of OMOXIN polypeptide. More preferably the invention is directed to purified, isolated, or recombinant soluble fragments of OMOXIN polypeptide. More preferably the invention is directed to said soluble fragment of OMOXIN polypeptide, wherein said soluble fragment binds LIGAND and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-
20 like activity or described herein, and wherein said soluble fragment of OMOXIN polypeptide does not activate OMOXIN. Preferably said soluble fragment of OMOXIN polypeptide blocks or inhibits LIGAND binding to OMOXIN. In preferred embodiments, said soluble fragment of OMOXIN polypeptide comprises, consists essentially of, or consists of, at least 6 and not more than 143 consecutive amino acids of SEQ ID NO:2, more preferably of amino acids comprising the
25 extracellular domain of OMOXIN. Preferred said soluble fragment of OMOXIN comprises the extracellular domain of mature OMOXIN polypeptide. Particularly preferred soluble fragment of OMOXIN comprises amino acids 26-157, 26-159 or 26-168 of SEQ ID NOs: 2, 4 or 6 where it is understood that amino acid 26 is predicted to be the N-terminal amino acid of the mature OMOXIN polypeptide absent the putative signal peptide. In other preferred embodiments, said soluble
30 fragment of OMOXIN polypeptide comprises an amino acid sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the corresponding consecutive amino acids of SEQ ID NO:2. Further preferred embodiments include heterologous polypeptides comprising a OMOXIN polypeptide of the invention. In further preferred embodiment, a OMOXIN polypeptide of the invention is conjugated at its N- or C-terminus to an antibody Fc region or portion
35 thereof.

In a further preferred embodiment, the invention is directed to a OMOXIN ANTAGONIST, wherein said ANTAGONIST is an antibody that specifically binds OMOXIN. More preferably the invention is directed to said OMOXIN antibody, wherein said OMOXIN antibody binds OMOXIN and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said OMOXIN antibody does not activate OMOXIN. Preferably said OMOXIN antibody blocks or inhibits LIGAND binding to OMOXIN.

In a further preferred embodiment, the invention is directed to a OMOXIN ANTAGONIST, wherein said ANTAGONIST is a compound excluding said soluble fragment of OMOXIN polypeptide and said OMOXIN antibody (e.g., small organic molecule, protein, peptide). More preferably the invention is directed to said compound, wherein said compound binds to OMOXIN and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said compound does not activate OMOXIN. Preferably said compound that binds to OMOXIN blocks or inhibits LIGAND binding to OMOXIN. Further more preferably the invention is directed to said compound, wherein said compound blocks or inhibits LIGAND activity exclusive of binding to OMOXIN, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said compound does not activate OMOXIN. Further more preferably the invention is directed to said compound, wherein said compound blocks or inhibits OMOXIN expression and wherein said compound does not have LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said compound does not activate OMOXIN.

In a further preferred embodiment, the invention is directed to a OMOXIN ANTAGONIST, wherein said ANTAGONIST is a variant or fragment of LIGAND polypeptide. More preferably the invention is directed to said variant or fragment of LIGAND polypeptide, wherein said variant or fragment of LIGAND polypeptide binds OMOXIN and blocks LIGAND activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or described herein, and wherein said variant or fragment of LIGAND polypeptide does not activate OMOXIN. Preferably said variant or fragment of LIGAND polypeptide blocks or inhibits LIGAND binding to OMOXIN. More preferably the invention is directed to said variant or fragment of LIGAND polypeptide, wherein said variant or fragment of LIGAND polypeptide inhibits the induction, enhancement, or potentiation of said biological activity exclusive of binding to OMOXIN.

In a further preferred embodiment, the invention is directed to a OMOXIN ANTAGONIST that selectively binds to a polypeptide comprising the extracellular domain of OMOXIN.

APM1. Preferred gAPM1 polypeptide fragment is selected from amino acids 18-244, 34-244, 49-244, 56-244, 59-244, 66-244, 69-244, 78-244, 85-244, 93-244, 101-244, 102-244, 103-244, 104-244, 107-244, 110-244, or 113-244, wherein said numbering of said amino acids within APM1 amino acid sequence is understood to be taken from said APM1 amino acid sequence presented in Table 2.

C2P. Preferred gC2P polypeptide fragment is selected from amino acids 20-333, 25-333, 43-333, 45-333, 46-333, 50-333, 53-333, 61-333, 67-333, 74-333, 75-333, 77-333, 81-333, 82-333, 86-333, 89-333, 95-333, 100-333, 104-333, 113-333, 116-333, 125-333, 128-333, 140-333, 160-333, 164-333, 179-333, 182-333, 185-333, 188-333, 191-333, 193-333, or 202-333, wherein said numbering of said amino acids within C2P amino acid sequence is understood to be taken from said C2P amino acid sequence presented in Table 2.

ZADJ-2. Preferred gZADJ-2 polypeptide fragment is selected from amino acids 16-285, 25-285, 26-285, 29-285, 30-285, 91-285, 93-285, 97-285, 98-285, 99-285, 105-285, 109-285, 112-285, 120-285, 126-285, 127-285, 130-285, 132-285, 133-285, 134-285, or 150-285, wherein said numbering of said amino acids within ZADJ-2 amino acid sequence is understood to be taken from said ZADJ-2 amino acid sequence presented in Table 2.

ZADJ-7. Preferred gZADJ-7 polypeptide fragment is selected from amino acids 31-303, 39-303, 78-303, 81-303, 84-303, 85-303, 88-303, 91-303, 97-303, 99-303, 109-303, 117-303, 118-303, 127-303, 139-303, 142-303, 155-303, or 162-303, wherein said numbering of said amino acids within ZADJ-7 amino acid sequence is understood to be taken from said ZADJ-7 amino acid sequence presented in Table 2.

Most preferred LIGAND is APM1 or C2P. Particularly most preferred LIGAND is APM1.

In a further preferred embodiment, said ANTAGONIST is able to raise circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

Further preferred said ANTAGONISTS are those that significantly inhibit muscle lipid or free fatty acid oxidation stimulated by its LIGAND. Further preferred said ANTAGONISTS are those that cause C2C12 cells differentiated in the presence of LIGAND to undergo at least 10%, 20%, 30%, 35%, or 40% less oleate oxidation as compared to untreated cells.

Further preferred said ANTAGONISTS are those that inhibit by at least 10%, 20%, 30%, 35%, or 40% the increase in leptin uptake stimulated by LIGAND polypeptide in a liver cell line [preferably BPRCL mouse liver cells (ATCC CRL-2217)] as compared to untreated cells.

Further preferred said ANTAGONISTS are those that significantly increase the postprandial increase in plasma free fatty acids, particularly following a high fat meal.

Further preferred said ANTAGONISTS are those that significantly increase ketone body production, particularly following a high fat meal.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in skeletal muscle cells stimulated by LIGAND.

5 Further preferred said ANTAGONISTS are those that decrease glucose uptake in adipose cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in neuronal cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in red blood
10 cells stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that decrease glucose uptake in the brain stimulated by LIGAND.

Further preferred said ANTAGONISTS are those that significantly increase the postprandial increase in plasma glucose following a meal, particularly a high carbohydrate meal.

15 Further preferred said ANTAGONISTS are those that significantly facilitate the postprandial increase in plasma glucose following a meal, particularly a high fat or a high carbohydrate meal.

Further preferred said ANTAGONISTS are those that reduce the insulin sensitivity stimulated by LIGAND.

20 Further preferred said ANTAGONISTS are those that increase body mass, wherein said increase in body mass is comprised of a change in mass of the subcutaneous adipose tissue.

Further preferred said ANTAGONISTS are those that increase body mass, wherein said increase in body mass is comprised of a change in mass of the visceral (omental) adipose tissue.

In a thirteenth aspect, the invention features a pharmaceutical or physiologically acceptable
25 composition comprising, consisting essentially of, or consisting of, said ANTAGONIST described in the twelfth aspect and, alternatively, a pharmaceutical or physiologically acceptable diluent.

In a fourteenth aspect, the invention features a method of increasing body mass comprising providing or administering to individuals in need of increasing body mass said pharmaceutical or physiologically acceptable composition described in the thirteenth aspect.

30 In a fifteenth aspect, the invention features a method of preventing or treating disorders associated with excessive weight loss comprising providing or administering to an individual in need of such treatment said pharmaceutical or physiologically acceptable composition described in the thirteenth aspect. Preferably said disorder is selected from the group consisting of cachexia,

wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia. Said disorders associated with excessive weight loss are comprised of those mediated by tumor necrosis factor (TNFalpha) alone, those mediated by TNFalpha plus one or more additional factors, and those mediated only by one or more factors
5 exclusive of TNFalpha. Said factors include, but are not restricted to, macrophage migration inhibitory factor, interleukin 1, and interleukin 6. In preferred embodiments, said individual is a mammal, preferably a human.

In related aspects, embodiments of the present invention includes methods of causing or inducing a desired biological response in an individual comprising the steps of: providing or
10 administering to an individual a composition comprising ANTAGONIST, wherein said biological response is selected from the group consisting of:

- (a) raising circulating (either blood, serum, or plasma) levels (concentration) of free fatty acids (FFA) or triglycerides (TG);
- (b) raising circulating (either blood, serum or plasma) levels (concentration) of glucose;
- 15 (c) raising circulating (either blood, serum or plasma) levels (concentration) of triglycerides;
- (d) inhibiting muscle lipid or free fatty acid oxidation;
- (c) inhibiting leptin uptake in the liver or liver cells;
- (e) increasing the postprandial increase in plasma free fatty acids, particularly following
20 a high fat meal; and,
- (f) increasing or eliminating ketone body production, particularly following a high fat meal;
- (g) reducing tissue sensitivity to insulin, particularly muscle, adipose, liver or brain,

and further wherein said biological response is greater than a transient response; or alternatively
25 wherein said biological response is sustained. In further preferred embodiments, the present invention of said pharmaceutical or physiologically acceptable composition can be used as a method of increasing body mass in some persons with cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia.

In further preferred embodiments, the present invention of said pharmaceutical or
30 physiologically acceptable composition further provides a method for the use as an insulin desensitiser, wherein the sensitivity of a cell or tissue to insulin is reduced.

In a sixteenth aspect, the invention features a method of making the OMOXIN polypeptide described in the twelfth aspect, wherein said method is selected from the group consisting of

proteolytic cleavage, recombinant methodology and artificial synthesis. In a preferred embodiment, proteolytic cleavage is carried out using trypsin, plasmin, or collagenase.

In a seventeenth aspect, the invention features a use of ANTAGONIST described in the twelfth aspect for the preparation of a medicament for the treatment of disorders associated with
5 excessive weight loss and/or for increasing body mass. Preferably, said disorder is selected from the group consisting of cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia. In preferred embodiments, said individual is a mammal, preferably a human.

In an eighteenth aspect, the invention provides ANTAGONIST of the twelfth aspect of the
10 invention, or a composition of the thirteenth aspect of the invention, for use in a method of treatment of the human or animal body.

In a nineteenth aspect, the invention features methods of increasing body weight comprising providing to an individual said pharmaceutical or physiologically acceptable composition described in the thirteenth aspect, or ANTAGONIST described in the twelfth aspect. Where the increase of
15 body weight is practiced for cosmetic purposes, the individual has a BMI of no greater than 25 and at least 20. In embodiments for the treatment of disorders associated with excessive weight loss, the individual may have a BMI no greater than 20. One embodiment for the treatment of disorders associated with excessive weight loss provides for the treatment of individuals with BMI values of no greater than 15. Alternatively, for increasing the body weight of an individual, the BMI value
20 should be at least 15 and no more than 20.

In a twentieth aspect, the invention features the pharmaceutical or physiologically acceptable composition described in the thirteenth aspect for increasing body mass and/or for treatment of disorders associated with excessive weight loss. Preferably, said disorder is selected from the group consisting of cachexia, wasting, cancer-related weight loss, AIDS-related weight
25 loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia. In preferred embodiments, said individual is a mammal, preferably a human.

In a twenty-first aspect, the invention features the pharmaceutical or physiologically acceptable composition described in the thirteenth aspect for increasing body weight for cosmetic reasons.

In a preferred aspect of the methods above and disclosed herein, the amount of
30 ANTAGONIST administered to an individual is sufficient to bring levels of OMOXIN activation to their normal levels (levels in healthy individuals). "Normal levels" of OMOXIN activation may be followed using surrogate markers including circulating (either blood, serum or plasma) levels (concentration) of: (i) free fatty acids, (ii) glucose, and/or (iii) triglycerides.

Table 1(A-C) lists known or predicted biologic structural and functional domains for the OMOXIN polypeptide of SEQ ID NOs: 2, 4 or 6 of the present invention, including the signal peptide, extracellular (EC) domain, transmembrane domain, and intracellular (IC) domain.

Table 2 lists the amino acid sequence of full-length APM1, C2P, ZADJ-2 and ZADJ-7 polypeptide. The total number of amino acids is given in parentheses. The predicted signal peptide is indicated in bold. The collagen-like region is indicated by dotted line. The region between the predicted signal peptide and the collagen-like region is the N-terminally disposed unique region. The globular C-terminal C1q homology domain is indicated by single underline. The NGLXXD amino acid motif C-terminally disposed within the globular domain is indicated by double underline.

It is taken to be understood that C2P herein encompasses variants comprising the substitution of valine for methionine at position 219 and/or the substitution of methionine for valine at position 301.

Structure of OMOXIN Polypeptide

The full-length OMOXIN polypeptide of SEQ ID NO: 2 is comprised of at least 4 distinct regions including:

1. an N-terminal putative signal peptide comprising amino acids from about amino acids 1-25 of SEQ ID NO: 2;
2. an extracellular domain comprising a LIGAND binding portion (and Cys-rich regions) and comprising amino acids from about amino acids 26-168 of SEQ ID NO: 2;
3. a transmembrane domain comprising amino acids from about amino acids 169-191 of SEQ ID NO: 2; and
4. an intracellular domain comprising amino acids from about amino acids 192-423 of SEQ ID NO: 2.

The full-length OMOXIN polypeptide of SEQ ID NO: 4 is comprised of at least 4 distinct regions including:

1. an N-terminal putative signal peptide comprising amino acids from about amino acids 1-25 of SEQ ID NO: 4;
2. an extracellular domain comprising a LIGAND binding portion (and Cys-rich regions) and comprising amino acids from about amino acids 26-168 of SEQ ID NO: 4;
3. a transmembrane domain comprising amino acids from about amino acids 169-191 of SEQ ID NO: 4; and
4. an intracellular domain comprising amino acids from about amino acids 192-417 of SEQ ID NO: 4.

The full-length OMOXIN polypeptide of SEQ ID NO: 6 is comprised of at least 4 distinct regions including:

1. an N-terminal putative signal peptide comprising amino acids from about amino acids 1-25 of SEQ ID NO: 6;
- 5 2. an extracellular domain comprising a LIGAND binding portion (and Cys-rich regions) and comprising amino acids from about amino acids 26-168 of SEQ ID NO: 6;
3. a transmembrane domain comprising amino acids from about amino acids 169-191 of SEQ ID NO: 6; and
- 10 4. an intracellular domain comprising amino acids from about amino acids 192-328 of SEQ ID NO: 6.

Brief Description of Sequence Listing

SEQ ID NOs: 1, 3 and 5 are the nucleotide sequences of cDNA with an open reading frame which location is indicated as features. When appropriate, the locations of the potential
15 polyadenylation site and polyadenylation signal are also indicated.

SEQ ID NOs: 2, 4 and 6 is the amino acid sequence of protein encoded by the cDNA of SEQ ID NOs: 1, 3 and 5, respectively. SEQ ID NOs: 2, 4, 6 and 7 represent splice variants of the OMOXIN gene.

The appended Sequence Listing is hereby incorporated by reference in its entirety.

20 Detailed Description

Definitions

Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

The term "isolated" requires that the material be removed from its original environment (e.
25 g., the natural environment if the material is naturally occurring).

The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

30 As used interchangeably herein, the term "polynucleotide(s)" include RNA or DNA (either single or double stranded, coding, complementary or antisense), or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form (although each of the above species may be particularly specified).

The terms “complementary” or “complement thereof” are used herein to refer to the sequences of polynucleotides that are capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region.

The terms “polypeptide” and “protein”, used interchangeably herein, refer to a polymer of
5 amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude chemical or post-expression modifications of the polypeptides of the invention, although chemical or post-expression modifications of these polypeptides may be included excluded as specific embodiments.

10 As used herein, the terms “recombinant polynucleotide” and “polynucleotide construct” are used interchangeably to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment. In particular, these terms mean that the polynucleotide or cDNA is adjacent to “backbone” nucleic acid to which it is not adjacent in
15 its natural environment.

The term “recombinant polypeptide” is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

20 As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship.

As used herein, the term “non-human animal” refers to any non-human animal, including insects, birds, rodents and more usually mammals. Both the terms “animal” and “mammal” expressly embrace human subjects unless preceded with the term “non-human”.

25 The term “domain” refers to an amino acid fragment with specific biological properties. This term encompasses all known structural and linear biological motifs.

As used herein, the term “receptor” refers to a polypeptide to which a “ligand” binds and through which said “ligand” elicits a biological response comprised of biological activities. Said receptor is preferably OMOXIN of the present invention. Said “ligand” is preferably LIGAND of
30 the present invention. By “receptor activation” is intended “ligand”-mediated alteration of said receptor polypeptide, wherein said alteration is selected from but not limited to the group consisting of receptor alterations associated with said biological response.

As used herein, the term “AGONIST” refers to naturally occurring and synthetic compounds capable of inducing, enhancing, or potentiating a biological response comprised of biological
35 activities.

As used herein, the term "ANTAGONIST" refers to naturally occurring and synthetic compounds capable of inhibiting a biological response, inhibiting the induction of a biological response, or inhibiting the potentiation of a biological response, wherein said biological response is comprised of biological activities.

5 Without being limited by theory, the compounds/polypeptides of the invention are capable of modulating the partitioning of dietary lipids between the liver and peripheral tissues, and are thus believed to treat "diseases involving the partitioning of dietary lipids between the liver and peripheral tissues." The term "peripheral tissues" is meant to include muscle and adipose tissue. In preferred embodiments, the compounds/polypeptides of the invention partition the dietary lipids
10 toward or away from the muscle. In alternative preferred embodiments, the dietary lipids are partitioned toward or away from the adipose tissue. In other preferred embodiments, the dietary lipids are partitioned toward or away from the liver. In yet other preferred embodiments, the compounds/polypeptides of the invention increase or decrease the oxidation of dietary lipids, preferably free fatty acids (FFA) by the muscle. Dietary lipids include, but are not limited to
15 triglycerides and free fatty acids.

Preferred diseases believed to involve the partitioning of dietary lipids include obesity-related diseases and disorders such as obesity, insulin resistance, atherosclerosis, atheromatous disease, heart disease, hypertension, stroke, Syndrome X, Noninsulin Dependent Diabetes Mellitus (NIDDM, or Type II diabetes) and Insulin Dependent Diabetes Mellitus (IDDM or Type I diabetes).
20 Diabetes-related complications to be treated by the methods of the invention include microangiopathic lesions, ocular lesions, retinopathy, neuropathy, and renal lesions. Heart disease includes, but is not limited to, cardiac insufficiency, coronary insufficiency, and high blood pressure. Other obesity-related disorders to be treated by compounds of the invention include hyperlipidemia and hyperuricemia. Yet other disorders of the invention include disorders associated with excessive
25 weight loss such as cachexia, wasting, cancer-related weight loss, AIDS-related weight loss, chronic inflammatory disease-related weight loss, anorexia, and bulimia.

The terms "comprising", "consisting of" and "consisting essentially of" may be interchanged for one another throughout the instant application, although each retains its normal definition. The term "having" has the same meaning as "comprising" and may be replaced with either the term
30 "consisting of" or "consisting essentially of".

Polypeptides of the Invention

Preferably, polypeptides of the invention are recombinantly produced using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide is operably linked to a promoter into an expression vector suitable for any convenient host. Both
35 eukaryotic and prokaryotic host systems are used in forming recombinant polypeptides. The

polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use.

Consequently, a further embodiment of the present invention is a method of making a polypeptide, said method comprising the steps of

- 5 a) obtaining a cDNA encoding said polypeptide;
- b) inserting said cDNA in an expression vector such that the cDNA is operably linked to a promoter; and
- c) introducing said expression vector into a host cell whereby said host cell produces said polypeptide.

10 In one aspect of this embodiment, the method further comprises the step of isolating the polypeptide. Another embodiment of the present invention is a polypeptide obtainable by the method described in the preceding paragraph.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a
15 variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). In preferred embodiment, recombinant polypeptides of the invention are expressed in mammalian cells.

The invention is drawn, *inter alia*, to isolated, purified or recombinant polypeptides. OMOXIN polypeptides of the invention are useful for increasing (ANTAGONISTS of OMOXIN)
20 body weight either as a cosmetic treatment or for treatment or prevention of diseases and disorders as discussed or described herein. OMOXIN polypeptides are also useful *inter alia* in screening assays for AGONISTS or ANTAGONISTS of gene activity and for raising OMOXIN-specific antibodies. When used for cosmetic treatments, or for the treatment or prevention of diseases, disorders, or conditions, one or more OMOXIN polypeptides can be provided to a subject. Thus,
25 various fragments of the full-length protein can be combined into a "cocktail" for use in the various treatment regimens. LIGAND polypeptides of the invention are useful for reducing (AGONISTS of OMOXIN) body weight either as a cosmetic treatment or prevention of diseases and disorders as discussed or described herein.

The OMOXIN polypeptides of the present invention are preferably provided in an isolated
30 form, and may be partially or substantially purified.

Modifying OMOXIN biological activity

Modifying endogenous OMOXIN biological activity is expressly contemplated by the present invention. The present invention further relates to compounds able to modulate OMOXIN

biological activity and methods to use these compounds. Such compounds may interact with OMOXIN polypeptides directly or indirectly.

Candidate AGONISTS and ANTAGONISTS Obtained by Optical Biosensor Methods

Compounds interacting with a polypeptide comprising OMOXIN extracellular domain can be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo *et al.* (1995), the disclosures of which are incorporated by reference. This technique permits the detection of interactions between molecules in real time, without the need of labeled molecules. This technique, which is based on the surface plasmon resonance (SPR) phenomenon, is presented in more detail in Example 1.

Compounds Modulating OMOXIN Biological Activity

Another method of screening for compounds that modulate OMOXIN biological activity is by measuring the effects of test compounds on specific biological activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, in a host cell. In one embodiment, the present invention relates to a method of identifying an agent that alters OMOXIN activity, wherein a nucleic acid construct comprising the polynucleotide of SEQ ID NO:1 or a fragment thereof encoding full-length OMOXIN polypeptide is introduced into a mammalian host cell. The transfected mammalian host cells are maintained under conditions appropriate for expression of the encoded OMOXIN, whereby the nucleic acid is expressed. The host cells are then contacted with a compound to be assessed (an agent) and an activity of the cells is detected in the presence of the compound to be assessed, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein. Detection of a change in said activity for said transfected host cell, but not in untransfected host cell, in the presence of the agent indicates that the agent alters OMOXIN activity. In a particular embodiment, the invention relates to a method of identifying an agent which is an activator (AGONIST) of OMOXIN activity, wherein detection of an increase of said activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, in the presence of the agent indicates that the agent activates OMOXIN activity. In another particular embodiment, the invention relates to a method of identifying an agent which is an inhibitor (ANTAGONIST) of OMOXIN activity, wherein detection of a decrease of said activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, in the presence of the agent indicates that the agent inhibits OMOXIN activity.

Detection of a change in said OMOXIN activity, said activity being selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity or as described herein, can be performed using a variety of techniques as described for representative activities in Examples provided herein.

In a particular embodiment a high throughput screen can be used to identify agents that activate (enhance) or inhibit OMOXIN activity (See e.g., PCT publication WO 98/45438, which disclosure is hereby incorporated by reference in its entirety).

Methods of Screening for Compounds Modulating OMOXIN Activity

5 The present invention also relates to methods of screening compounds for their ability to modulate (e.g. increase or inhibit) the activity or expression of OMOXIN. More specifically, the present invention relates to methods of testing compounds for their ability either to increase or to decrease activity of OMOXIN. The assays are performed *in vitro* or *in vivo*.

10 The present invention relates to a method for the screening of a candidate substance for interaction with a polypeptide comprising OMOXIN extracellular domain, said method comprising the following steps:

- a) providing said polypeptide comprising OMOXIN extracellular domain;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
- 15 d) detecting the complexes formed between said polypeptide and said candidate substance.

20 The invention further relates to a method for the production of a pharmaceutical composition comprising a method for the screening of a candidate substance that interact with a OMOXIN polypeptide, fragments or variants thereof and furthermore mixing the identified substance with a pharmaceutically acceptable carrier.

The present invention relates to a method for the screening of a candidate substance for the capacity to increase expression of OMOXIN, said method comprising the following steps:

- a) isolating mRNA from cells which have or have not been contacted with said candidate substance;
- 25 b) carrying out a Northern blot analysis with labeled cDNA probe encoding all or part of OMOXIN polypeptide;
- c) wherein increased signal in cells having been contacted with said candidate substance over that of uncontacted cells is taken to indicate that said candidate substance increases expression of OMOXIN and is an AGONIST of OMOXIN activity; and
- 30 d) wherein decreased signal in cells having been contacted with said candidate substance over that of uncontacted cells is taken to indicate that said candidate

substance decreases expression of OMOXIN and is an ANTAGONIST of OMOXIN activity.

Methods of isolating mRNA and carrying out Northern blot analysis are well known to those of ordinary skill in the art.

5 Preparation of Antibody Compositions

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the OMOXIN protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the
10 protein can then be prepared by methods well known to those of ordinary skill in the art.

Preferably the present invention includes monoclonal and polyclonal antibodies that specifically bind OMOXIN polypeptide fragment comprising the extracellular domain of mature OMOXIN polypeptide. Particularly preferred soluble fragment of OMOXIN comprises amino acids 26-157, 26-159 or 26-168 of SEQ ID NOs: 2, 4 or 6 where it is understood that amino acid 26 is
15 predicted to be the N-terminal amino acid of the mature OMOXIN polypeptide absent the putative signal peptide.

EXAMPLES

The following Examples are provided for illustrative purposes and not as a means of limitation. One of ordinary skill in the art would be able to design equivalent assays and methods
20 based on the disclosure herein all of which form part of the instant invention.

EXAMPLE 1: Use of Biacore Technology to Detect Specific Binding of a Test Compound to Polypeptide Fragment Comprising OMOXIN Extracellular Domain

Biacore utilizes a biosensor technology for monitoring interactions between two or more molecules in real time, without the use of labels. The molecular classes than can be studied are
25 diverse, ranging from proteins, peptides, nucleic acids, carbohydrates, and lipids to low molecular weight substances and pharmaceuticals.

The detection principle is based on the optical phenomena of surface plasmon resonance, which detects changes in refractive index close to a biosensor surface. In a typical experiment one of the interacting molecules is immobilized or captured (here, polypeptide fragment comprising
30 OMOXIN extracellular domain) to a flexible dextran layer close to the sensor surface. The interacting partner (here, test compound) is flowed across that surface. If an interaction occurs between the two molecules, there is a resulting increase in signal due to the increase in mass at the chip surface.

Soluble polypeptide fragment comprising OMOXIN extracellular domain is attached to the sensor surface via amine coupling chemistry. The dextran is activated using N-hydroxysuccinimide and N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride for 7 minutes. Said OMOXIN polypeptide fragment is diluted in 10mM Na Acetate pH 5.0 at a concentration of 10µg/ml and injected over the activated surface for 7 minutes. The surface is then blocked for 7 minutes using ethanolamine to remove any remaining esters. A blank flow cell absent said OMOXIN polypeptide fragment is set up in parallel and used as a control surface. The running buffer is HBS-EP (0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% Surfactant P20) and the instrument temperature is 25°C.

The test compound is filtered through an Ultrafree-0.5 Centrifugal Filter Device and resuspended in HBS-EP running buffer. The test compound is then diluted 1:10 in HBS-EP and injected over the said OMOXIN polypeptide fragment surface and the blank control surface for 1 minute at a flow rate of 50 µl/min. The sensorgrams from the receptor surface and the control surface are aligned and overlaid.

To obtain the specific binding, the control surface was subtracted from the active surface comprised of said OMOXIN polypeptide fragment.

Example 2: Effect of LIGAND on Muscle Cell Fatty Acid Oxidation

C2C12 cells are differentiated in the presence or absence of 2 µg/mL LIGAND for 4 days. On day 4, oleate oxidation rates are determined by measuring conversion of 1-¹⁴C-oleate (0.2 mM) to ¹⁴CO₂ for 90 min. This experiment can be used to screen for active polypeptides and peptides as well as AGONISTS and ANTAGONISTS or activators and inhibitors of LIGAND receptor.

The effect of LIGAND on the rate of oleate oxidation can be compared in differentiated C2C12 cells (murine skeletal muscle cells; ATCC, Manassas, VA CRL-1772) and in a hepatocyte cell line (Hepa1-6; ATCC, Manassas, VA CRL-1830). Cultured cells are maintained according to manufacturer's instructions. The oleate oxidation assay is performed as previously described (Muoio et al (1999) Biochem J 338;783-791). Briefly, nearly confluent myocytes are kept in low serum differentiation media (DMEM, 2.5% Horse serum) for 4 days, at which time formation of myotubes became maximal. Hepatocytes are kept in the same DMEM medium supplemented with 10% FCS for 2 days. One hour prior to the experiment the media is removed and 1 mL of preincubation media (MEM, 2.5% Horse serum, 3 mM glucose, 4 mM Glutamine, 25 mM Hepes, 1% FFA free BSA, 0.25 mM Oleate, 5 µg/mL gentamycin) is added. At the start of the oxidation experiment ¹⁴C-Oleic acid (1µCi/mL, American Radiolabelled Chemical Inc., St. Louis, MO) is added and cells are incubated for 90 min at 37°C in the absence/presence of 2.5 µg/mL LIGAND. After the incubation period 0.75 mL of the media is removed and assayed for ¹⁴C-oxidation products as described below for the muscle FFA oxidation experiment.

EXAMPLE 3: Effect of LIGAND on *In Vitro* Glucose Uptake by Muscle Cells

L6 Muscle cells are obtained from the European Culture Collection (Porton Down) and are used at passages 7-11. Cells are maintained in standard tissue culture medium DMEM, and glucose uptake is assessed using [³H]-2-deoxyglucose (2DG) with or without LIGAND in the presence or
5 absence of insulin (10⁻⁸ M) as has been previously described (Walker, P.S. et al. (1990) Glucose transport activity in L6 muscle cells is regulated by the coordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription. JBC 265(3):1516-1523; and Kilp, A. et al. (1992) Stimulation of hexose transport by metformin in L6 muscle cells in culture. Endocrinology 130(5):2535-2544, which disclosures are hereby incorporated by reference in their
10 entireties). Uptake of 2DG is expressed as the percentage change compared with control (no added insulin or LIGAND). Values are presented as mean ± SEM of sets of 4 wells per experiment. Differences between sets of wells are evaluated by Student's t test, probability values p<0.05 are considered to be significant.

EXAMPLE 4: Effect of LIGAND on Mice Fed a High-Fat Diet

15 Experiments are performed using approximately 6 week old C57Bl/6 mice (8 per group). All mice are housed individually. The mice are maintained on a high fat diet throughout each experiment. The high fat diet (cafeteria diet; D12331 from Research Diets, Inc.) has the following composition: protein kcal% 16, sucrose kcal% 26, and fat kcal% 58. The fat is primarily composed of coconut oil, hydrogenated.

20 After the mice are fed a high fat diet for 6 days, micro-osmotic pumps are inserted using isoflurane anesthesia, and are used to provide LIGAND, saline, and an irrelevant peptide to the mice subcutaneously (s.c.) for 18 days. LIGAND is provided at doses of 100, 50, 25, and 2.5 µg/day and the irrelevant peptide is provided at 10 µg/day. Body weight is measured on the first, third and fifth day of the high fat diet, and then daily after the start of treatment. Final blood samples are taken by
25 cardiac puncture and are used to determine triglyceride (TG), total cholesterol (TC), glucose, leptin, and insulin levels. The amount of food consumed per day is also determined for each group.

EXAMPLE 5: Effect of LIGAND on Plasma Free Fatty Acid in C57 BL/6 Mice

The effect of LIGAND on postprandial lipemia (PPL) in normal C57BL/6/J mice is tested.

The mice used in this experiment are fasted for 2 hours prior to the experiment after which a
30 baseline blood sample is taken. All blood samples are taken from the tail using EDTA coated capillary tubes (50 µL each time point). At time 0 (8:30 AM), a standard high fat meal (6g butter, 6 g sunflower oil, 10 g nonfat dry milk, 10 g sucrose, 12 mL distilled water prepared fresh following Nb#6, JF, pg.1) is given by gavage (vol.=1% of body weight) to all animals.

Immediately following the high fat meal, 25µg a LIGAND is injected i.p. in 100 µL saline.
35 The same dose (25µg/mL in 100µL) is again injected at 45 min and at 1 hr 45 min. Control animals are injected with saline (3x100µL). Untreated and treated animals are handled in an alternating mode.

Blood samples are taken in hourly intervals, and are immediately put on ice. Plasma is prepared by centrifugation following each time point. Plasma is kept at -20°C and free fatty acids (FFA), triglycerides (TG) and glucose are determined within 24 hours using standard test kits (Sigma and Wako). Due to the limited amount of plasma available, glucose is determined in
5 duplicate using pooled samples. For each time point, equal volumes of plasma from all 8 animals per treatment group are pooled.

EXAMPLE 6: Effect of LIGAND on Plasma FFA, TG and Glucose in C57 BL/6 Mice

Briefly, 14 mice re fasted for 2 hours prior to the experiment after which a baseline blood sample is taken. All blood samples are taken from the tail using EDTA coated capillary tubes (50
10 μL each time point). At time 0 (9:00AM), a standard high fat meal (see Example 6) is given by gavage (vol.=1% of body weight) to all animals. Immediately following the high fat meal, 4 mice are injected 25 μg of LIGAND i.p. in 100 μL saline. The same dose (25 μg in 100 μL) is again injected at 45 min and at 1 hr 45 min. A second treatment group receives 3 times 50 μg LIGAND at the same intervals. Control animals are injected with saline (3x100 μL). Untreated and treated
15 animals are handled in an alternating mode.

Blood samples are immediately put on ice. Plasma is prepared by centrifugation following each time point. Plasma is kept at -20°C and free fatty acids (FFA), triglycerides (TG) and glucose are determined within 24 hours using standard test kits (Sigma and Wako).

EXAMPLE 7: Effect of LIGAND on FFA following Epinephrine Injection

20 In mice, plasma free fatty acids increase after intragastric administration of a high fat/sucrose test meal. These free fatty acids are mostly produced by the activity of lipolytic enzymes *i.e.* lipoprotein lipase (LPL) and hepatic lipase (HL). In this species, these enzymes are found in significant amounts both bound to endothelium and freely circulating in plasma. Another source of plasma free fatty acids is hormone sensitive lipase (HSL) that releases free fatty acids from adipose
25 tissue after β -adrenergic stimulation. To test whether LIGAND also regulates the metabolism of free fatty acid released by HSL, mice are injected with epinephrine.

Two groups of mice are given epinephrine (5 μg) by intraperitoneal injection. A treated group is injected with a LIGAND (25 μg) one hour before and again together with epinephrine, while control animals receive saline. Plasma is isolated and free fatty acids and glucose are measured.

30 EXAMPLE 8: Effect of LIGAND on FFA following Intralipid Injection

Two groups of mice are intravenously (tail vein) injected with 30 μL bolus of Intralipid-20% (Clintec) to generate a sudden rise in plasma FFAs, thus by-passing intestinal absorption. (Intralipid is an intravenous fat emulsion used in nutritional therapy). A treated group (LIGAND-treated) is injected with LIGAND (25 μg) at 30 and 60 minutes before Intralipid is given, while control animals
35 receive saline. Plasma is isolated and FFAs are measured as described previously. The effect of LIGAND on the decay in plasma FFAs following the peak induced by Intralipid injection is then monitored.

EXAMPLE 9: Effect of LIGAND on Weight Gain and Weight Loss of Mice and on Maintenance of Weight Loss in Mice

In the first experiment, 10-week-old male C57BL/6J mice are put on a very high fat/sucrose purified diet for 19 days to promote weight gain; the average body weight at this time is 30g. The mice are then surgically implanted with an osmotic pump (Alzet, Newark, DE) delivering either 2.5 μ g/day of LIGAND or physiological saline. The mice are continued on the high fat diet and their body weight was recorded over the following 10-day period.

Weight gain by mice treated with saline in contradistinction to weight loss by mice treated with LIGAND is taken as evidence that in this inbred strain of normal mice, a continuous infusion of a daily low dose of LIGAND can prevent weight gain caused by high fat/sucrose feeding, in a sustainable way.

Data are expressed throughout as mean $\pm$ SEM; a p-value < 0.05 is considered statistically significant. Statistical analysis is typically done using either the unpaired Student's t test or the paired Student's t test.

Maintenance of weight loss in mice

In order to demonstrate the ability of LIGAND to maintain weight loss, normal mice are put on a reduced calorie diet to promote weight loss. The reduced calorie diet is continued until the mice lose 10% of their initial weight. A second group of mice are continued on the reduced calorie diet until the mice lose 20% of their initial weight. The mice are then surgically implanted with an osmotic pump (Alzet, Newark, DE) delivering either 2.5 μ g/day of LIGAND or physiological saline. The mice are returned to a normal diet and their body weights are recorded over a 10-day period. After 10 days, the outcome wherein mice treated with LIGAND have a lower weight than mice treated with saline is taken to provide evidence that treatment with LIGAND promotes the maintenance of weight loss.

EXAMPLE 10: Assessment of homotrimer formation by gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment.

Homotrimer formation by gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment is assessed using sedimentation equilibrium in analytical centrifuges, a method that determines molecular weight accurately and independently of other physical factors such as shape.

Candidate gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment homotrimer is purified, for example using a protocol comprising a method of gel filtration such as 16/60 superdex 200 gel filtration column (Amersham). Said purified candidate gAPM1, gC2P, gZADJ-2 or gZADJ-7 polypeptide fragment homotrimer protein concentration is made 3 μ M in 5.7 mM phosphate (pH 7.5), 137 mM NaCl, 2.7 mM KCl. Samples are centrifuged at 8,000 rpm for 18 hours at 10°C in a Beckman XL-A analytical ultracentrifuge before absorbance is recorded. The data are fit globally, using MacNonlin PPC [Johnson ML et al., Biophys J (1981) 36:575-8; Schuster TM et al., Curr Opin Struct Biol (1996) 6:650-8; Hensley P, Structure (1996) 4:367-73; the disclosures of which are

incorporated herein by reference in their entirety] to the following equation that describes the sedimentation of a homogeneous species: $Abs = B + A' \exp[H \times M (x^2 - x_0^2)]$ where Abs = absorbance at radius x, A' = absorbance at reference radius x_0 , $H = (1 - v\rho)\omega^2/2RT$, R = gas constant, T = temperature in Kelvin, v = partial specific volume = 0.71896131 mL/g, ρ = density of solvent = 1.0061 g/mL, ω = angular velocity in radians/s, M = apparent molecular weight, and B = solvent absorbance (blank).

TABLE 1(A-C)

10 Amino Acid Residues Comprising the Structural Domains of OMOXIN

Table 1A

SEQ ID NO: 2 Description

SIGNAL PEPTIDE	EC DOMAIN	TRANSMEMBRANE DOMAIN	IC DOMAIN
1-25	26-168	169-191	192-423

Table 1B

15 SEQ ID NO: 4 Description

SIGNAL PEPTIDE	EC DOMAIN	TRANSMEMBRANE DOMAIN	IC DOMAIN
1-25	26-168	169-191	192-417

Table 1C

SEQ ID NO: 6 Description

SIGNAL PEPTIDE	EC DOMAIN	TRANSMEMBRANE DOMAIN	IC DOMAIN
1-25	26-168	169-191	192-328

EC, extracellular domain; IC, intracellular domain

APM1, C2P, ZADJ-2 and ZADJ-7

>APM1 polypeptide sequence:

5 **MLLLGAVLLLLALPGHDQETTTQGPVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRD**
GTPGEKGEKGDPGLIGPKDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYRSAFSVGLET
YVTIPNMPIRFTKIFYNQONHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSFLKKDKAM
LFTYDQYQENNVDDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLYH
DTN (244)

10

> C2P polypeptide sequence:

MRIWWLLLAIEICTGNINSQDTCRQGHPIPGNPGHNGLPGRDGRDGAKGDKGDAGEPG
RPGSPGKDGTSGEKGGERGADGKVEAKGIKGDQSGRSPGKHGPKGLAGPMGEKGLRGETG
PQGQKGNGKGDVGPTGPEGPRGNIGPLGPTGLPGMPGPKGPKGEAGPTGPQGEVVRGIR
15 **GWKGDRGEKKGIGETLVLPKSAFTVGLTVLSKFPSSDMPKFDKILYNEFNHYDTAAGKFTC**
HIAGVYYFTYHITVFSRNVQVSLVKNVVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQ
VTGGERFNGLEADEDDDTTFTGFLLFSSP (333)

>ZADJ-2 polypeptide sequence:

20 **MIPWVLLACALPCAADPLLGAFAARRDFRKGSPQLVCSLPGPQGPPGPPGAPGPSGMMGRM**
GFPKGKDGDGHDGDRGDSGEEGPPGRTGNRGKPGPKGKAGAIGRAGPRGPKGVNGTPGK
HGTPGKKGPKGKKGEPGLPGPCSCSGHTKSAFSVAVTKSYPRELRPIKFDKILMNEGGHY
NASSGKFVCGVPGIYYFTYDITLANKHLAIGLVHNGQYRIRTFDANTGNHDTVASGSTILALK
QGDEVWLQIFYSEQNGLFYDPYWTDLSFTGFLIYADQDDPNEV (285)

25

>ZADJ-7 polypeptide sequence:

MGKEDTQETRTEPKMFVLLYVTSFAICASGQPRGNQLKGENYSPRYICSIPGLPGPPGPPG
ANGSPGPHGRIGLPGRDGRDGRKGEKGEKGTAGLRGKTGPLGLAGEKGDQGETGKKGPIG
PEGEKGEVGPPIGPPGPKGDRGEQGDPLPGVCRCGSIVLKSASFVSGITTSYPEERLPIIFNKVL
30 **FNEGEHYNPATGKFICAFPGIYYFSYDITLANKHLAIGLVHNGQYRIKTFDANTGNHDTVASG**
STVIYLQPEDEVWLEIFFTDQNGLESDPGWADSLFSGFLLYVDTDYLDSEDEL (303)

What is claimed is:

1. A method of screening for an AGONIST or an ANTAGONIST of OMOXIN activity.
- 5 2. The method of Claim 1, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, insulin-like activity, free fatty acid oxidation, and weight reduction.
3. An AGONIST or an ANTAGONIST of OMOXIN activity.
4. The AGONIST or the ANTAGONIST of Claim 3, wherein said activity is selected
10 from the group consisting of lipid partitioning, lipid metabolism, insulin-like activity, free fatty acid oxidation, and weight reduction.
5. A pharmaceutical or physiologically acceptable composition comprising, consisting essentially of, or consisting of the AGONIST or the ANTAGONIST of Claim 3.
6. A method of preventing or treating an obesity-related disease or disorder comprising
15 providing or administering to an individual in need of such treatment the composition of Claim 5.

SEQUENCE LISTING

<110> Genset

<120> TREATMENT OF METABOLIC DISORDERS WITH OMOXIN AGONISTS AND ANTAGONISTS

<130> 138.WO1

<150> 60/310,731

<151> 2001/08/07

<150> 60/310,784

<151> 2001/08/07

<150> 60/333,946

<151> 2001/11/19

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1489

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (65)...(1336)

<400> 1

```
ggacctgcag cctcccaggt ggctgggaag aactctccaa caataaatac atttgataag 60
aaag atg gct tta aaa gtg cta cta gaa caa gag aaa acg ttt ttc act 109
      Met Ala Leu Lys Val Leu Leu Glu Gln Glu Lys Thr Phe Phe Thr
        1             5             10             15

ctt tta gta tta cta ggc tat ttg tca tgt aaa gtg act tgt gaa tca 157
Leu Leu Val Leu Leu Gly Tyr Leu Ser Cys Lys Val Thr Cys Glu Ser
          20             25             30

gga gac tgt aga cag caa gaa ttc agg gat cgg tct gga aac tgt gtt 205
Gly Asp Cys Arg Gln Gln Glu Phe Arg Asp Arg Ser Gly Asn Cys Val
          35             40             45

ccc tgc aac cag tgt ggg cca ggc atg gag ttg tct aag gaa tgt ggc 253
Pro Cys Asn Gln Cys Gly Pro Gly Met Glu Leu Ser Lys Glu Cys Gly
          50             55             60

ttc ggc tat ggg gag gat gca cag tgt gtg gcg tgc cgg ctg cac agg 301
Phe Gly Tyr Gly Glu Asp Ala Gln Cys Val Ala Cys Arg Leu His Arg
          65             70             75

ttc aag gag gac tgg ggc ttc cag aaa tgc aag ccc tgt ctg gac tgc 349
Phe Lys Glu Asp Trp Gly Phe Gln Lys Cys Lys Pro Cys Leu Asp Cys
          80             85             90             95

gca gtg gtg aac cgc ttt cag aag gca aat tgt tca gcc acc agt gat 397
Ala Val Val Asn Arg Phe Gln Lys Ala Asn Cys Ser Ala Thr Ser Asp
          100            105            110

gcc atc tgc ggg gac tgc ttg cca gga ttt tat agg aag acg aaa ctt 445
Ala Ile Cys Gly Asp Cys Leu Pro Gly Phe Tyr Arg Lys Thr Lys Leu
          115            120            125
```

gtc ggc ttt caa gac atg gag tgt gtg cct tgt gga gac cct cct cct	493
Val Gly Phe Gln Asp Met Glu Cys Val Pro Cys Gly Asp Pro Pro Pro	
130 135 140	
cct tac gaa ccg cac tgt gcc agc aag gtc aac ctc gtg aag atc gcg	541
Pro Tyr Glu Pro His Cys Ala Ser Lys Val Asn Leu Val Lys Ile Ala	
145 150 155	
tcc acg gcc tcc agc cca cgg gac acg gcg ctg gct gcc gtt atc tgc	589
Ser Thr Ala Ser Ser Pro Arg Asp Thr Ala Leu Ala Ala Val Ile Cys	
160 165 170 175	
agc gct ctg gcc acc gtc ctg ctg gcc ctg ctc atc ctc tgt gtc atc	637
Ser Ala Leu Ala Thr Val Leu Leu Ala Leu Leu Ile Leu Cys Val Ile	
180 185 190	
tat tgt aag aga cag ttt atg gaa aag aaa ccc agc tgg tct ctg cgg	685
Tyr Cys Lys Arg Gln Phe Met Glu Lys Lys Pro Ser Trp Ser Leu Arg	
195 200 205	
tca cag gac att cag tac aac gag act gag ctg tcg tgt ttt gac aga	733
Ser Gln Asp Ile Gln Tyr Asn Glu Thr Glu Leu Ser Cys Phe Asp Arg	
210 215 220	
cct cag ctc cac gaa tat gcc cac aga gcc tgc tgc cag tgc cgc cgt	781
Pro Gln Leu His Glu Tyr Ala His Arg Ala Cys Cys Gln Cys Arg Arg	
225 230 235	
gac tca gtg cag acc tgc ggg ccg gtg cgc ttg ctc cca tcc atg tgc	829
Asp Ser Val Gln Thr Cys Gly Pro Val Arg Leu Leu Pro Ser Met Cys	
240 245 250 255	
tgt gag gag gcc tgc agc ccc aac ccg gcg act ctt ggt tgt ggg gtg	877
Cys Glu Glu Ala Cys Ser Pro Asn Pro Ala Thr Leu Gly Cys Gly Val	
260 265 270	
cat tct gca gcc agt ctt cag gca aga aac gca ggc cca gcc ggg gag	925
His Ser Ala Ala Ser Leu Gln Ala Arg Asn Ala Gly Pro Ala Gly Glu	
275 280 285	
atg gtg ccg act ttc ttc gga tcc ctc acg cag tcc atc tgt ggc gag	973
Met Val Pro Thr Phe Phe Gly Ser Leu Thr Gln Ser Ile Cys Gly Glu	
290 295 300	
ttt tca gat gcc tgg cct ctg atg cag aat ccc atg ggt ggt gac aac	1021
Phe Ser Asp Ala Trp Pro Leu Met Gln Asn Pro Met Gly Gly Asp Asn	
305 310 315	
atc tct ttt tgt gac tct tat cct gaa ctc act gga gaa gac att cat	1069
Ile Ser Phe Cys Asp Ser Tyr Pro Glu Leu Thr Gly Glu Asp Ile His	
320 325 330 335	
tct ctc aat cca gaa ctt gaa agc tca acg tct ttg gat tca aat agc	1117
Ser Leu Asn Pro Glu Leu Glu Ser Ser Thr Ser Leu Asp Ser Asn Ser	
340 345 350	
agt caa gat ttg gtt ggt ggg gct gtt cca gtc cag tct cat tct gaa	1165
Ser Gln Asp Leu Val Gly Gly Ala Val Pro Val Gln Ser His Ser Glu	
355 360 365	
aac ttt aca gca gct act gat tta tct aga tat aac aac aca ctg gta	1213
Asn Phe Thr Ala Ala Thr Asp Leu Ser Arg Tyr Asn Asn Thr Leu Val	

```

          370                      375                      380
gaa tca gca tca act cag gat gca cta act atg aga agc cag cta gat 1261
Glu Ser Ala Ser Thr Gln Asp Ala Leu Thr Met Arg Ser Gln Leu Asp
      385                      390                      395

cag gag agt ggc gct gtc atc cac cca gcc act cag acg tcc ctc cag 1309
Gln Glu Ser Gly Ala Val Ile His Pro Ala Thr Gln Thr Ser Leu Gln
400                      405                      410                      415

gta agg cag cga ctg ggt tcc ctg tga acacagcact gacttacagt 1356
Val Arg Gln Arg Leu Gly Ser Leu *
          420

agatcagaac tctgttccca gcataagatt tgggggaacc tggatgagtt tttttttttg 1416
catctttaat aatttcttat atgttgtaga gtatgtttta aaataaattt caagtatttt 1476
tttaaaaaac ttt 1489

```

<210> 2
 <211> 423
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 74
 <223> Polymorphic amino acid Ala or Thr

<221> VARIANT
 <222> 215
 <223> Polymorphic amino acid Glu or Gly

<221> VARIANT
 <222> 216
 <223> Polymorphic amino acid Thr or Ser

<221> VARIANT
 <222> 221
 <223> Polymorphic amino acid Phe or Leu

<221> VARIANT
 <222> 330
 <223> Polymorphic amino acid Thr or Ala

<221> VARIANT
 <222> 405
 <223> Polymorphic amino acid Val or Ile

```

<400> 2
Met Ala Leu Lys Val Leu Leu Glu Gln Glu Lys Thr Phe Phe Thr Leu
 1          5          10          15
Leu Val Leu Leu Gly Tyr Leu Ser Cys Lys Val Thr Cys Glu Ser Gly
      20          25          30
Asp Cys Arg Gln Gln Glu Phe Arg Asp Arg Ser Gly Asn Cys Val Pro
      35          40          45
Cys Asn Gln Cys Gly Pro Gly Met Glu Leu Ser Lys Glu Cys Gly Phe
      50          55          60
Gly Tyr Gly Glu Asp Ala Gln Cys Val Ala Cys Arg Leu His Arg Phe
      65          70          75          80
Lys Glu Asp Trp Gly Phe Gln Lys Cys Lys Pro Cys Leu Asp Cys Ala
      85          90          95
Val Val Asn Arg Phe Gln Lys Ala Asn Cys Ser Ala Thr Ser Asp Ala
      100          105          110

```

4

Ile Cys Gly Asp Cys Leu Pro Gly Phe Tyr Arg Lys Thr Lys Leu Val
 115 120 125
 Gly Phe Gln Asp Met Glu Cys Val Pro Cys Gly Asp Pro Pro Pro
 130 135 140
 Tyr Glu Pro His Cys Ala Ser Lys Val Asn Leu Val Lys Ile Ala Ser
 145 150 155 160
 Thr Ala Ser Ser Pro Arg Asp Thr Ala Leu Ala Ala Val Ile Cys Ser
 165 170 175
 Ala Leu Ala Thr Val Leu Leu Ala Leu Leu Ile Leu Cys Val Ile Tyr
 180 185 190
 Cys Lys Arg Gln Phe Met Glu Lys Lys Pro Ser Trp Ser Leu Arg Ser
 195 200 205
 Gln Asp Ile Gln Tyr Asn Glu Thr Glu Leu Ser Cys Phe Asp Arg Pro
 210 215 220
 Gln Leu His Glu Tyr Ala His Arg Ala Cys Cys Gln Cys Arg Arg Asp
 225 230 235 240
 Ser Val Gln Thr Cys Gly Pro Val Arg Leu Leu Pro Ser Met Cys Cys
 245 250 255
 Glu Glu Ala Cys Ser Pro Asn Pro Ala Thr Leu Gly Cys Gly Val His
 260 265 270
 Ser Ala Ala Ser Leu Gln Ala Arg Asn Ala Gly Pro Ala Gly Glu Met
 275 280 285
 Val Pro Thr Phe Phe Gly Ser Leu Thr Gln Ser Ile Cys Gly Glu Phe
 290 295 300
 Ser Asp Ala Trp Pro Leu Met Gln Asn Pro Met Gly Gly Asp Asn Ile
 305 310 315 320
 Ser Phe Cys Asp Ser Tyr Pro Glu Leu Thr Gly Glu Asp Ile His Ser
 325 330 335
 Leu Asn Pro Glu Leu Glu Ser Ser Thr Ser Leu Asp Ser Asn Ser Ser
 340 345 350
 Gln Asp Leu Val Gly Gly Ala Val Pro Val Gln Ser His Ser Glu Asn
 355 360 365
 Phe Thr Ala Ala Thr Asp Leu Ser Arg Tyr Asn Asn Thr Leu Val Glu
 370 375 380
 Ser Ala Ser Thr Gln Asp Ala Leu Thr Met Arg Ser Gln Leu Asp Gln
 385 390 395 400
 Glu Ser Gly Ala Val Ile His Pro Ala Thr Gln Thr Ser Leu Gln Val
 405 410 415
 Arg Gln Arg Leu Gly Ser Leu
 420

<210> 3

<211> 1660

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(1254)

<400> 3

atg gct tta aaa gtg cta cta gaa caa gag aaa acg ttt ttc act ctt 48
 Met Ala Leu Lys Val Leu Leu Glu Gln Glu Lys Thr Phe Phe Thr Leu
 1 5 10 15
 tta gta tta cta ggc tat ttg tca tgt aaa gtg act tgt gaa tca gga 96
 Leu Val Leu Leu Gly Tyr Leu Ser Cys Lys Val Thr Cys Glu Ser Gly
 20 25 30
 gac tgt aga cag caa gaa ttc agg gat cgg tct gga aac tgt gtt ccc 144
 Asp Cys Arg Gln Gln Glu Phe Arg Asp Arg Ser Gly Asn Cys Val Pro
 35 40 45

tgc aac cag tgt ggg cca ggc atg gag ttg tct aag gaa tgt ggc ttc	192
Cys Asn Gln Cys Gly Pro Gly Met Glu Leu Ser Lys Glu Cys Gly Phe	
50 55 60	
ggc tat ggg gag gat gca cag tgt gtg acg tgc cgg ctg cac agg ttc	240
Gly Tyr Gly Glu Asp Ala Gln Cys Val Thr Cys Arg Leu His Arg Phe	
65 70 75 80	
aag gag gac tgg ggc ttc cag aaa tgc aag ccc tgt ctg gac tgc gca	288
Lys Glu Asp Trp Gly Phe Gln Lys Cys Lys Pro Cys Leu Asp Cys Ala	
85 90 95	
gtg gtg aac cgc ttt cag aag gca aat tgt tca gcc acc agt gat gcc	336
Val Val Asn Arg Phe Gln Lys Ala Asn Cys Ser Ala Thr Ser Asp Ala	
100 105 110	
atc tgc ggg gac tgc ttg cca gga ttt tat agg aag acg aaa ctt gtc	384
Ile Cys Gly Asp Cys Leu Pro Gly Phe Tyr Arg Lys Thr Lys Leu Val	
115 120 125	
ggc ttt caa gac atg gag tgt gtg cct tgt gga gac cct cct cct cct	432
Gly Phe Gln Asp Met Glu Cys Val Pro Cys Gly Asp Pro Pro Pro Pro	
130 135 140	
tac gaa ccg cac tgt gcc agc aag gtc aac ctc gtg aag atc gcg tcc	480
Tyr Glu Pro His Cys Ala Ser Lys Val Asn Leu Val Lys Ile Ala Ser	
145 150 155 160	
acg gcc tcc agc cca cgg gac acg gcg ctg gct gcc gtt atc tgc agc	528
Thr Ala Ser Ser Pro Arg Asp Thr Ala Leu Ala Ala Val Ile Cys Ser	
165 170 175	
gct ctg gcc acc gtc ctg ctg gcc ctg ctc atc ctc tgt gtc atc tat	576
Ala Leu Ala Thr Val Leu Leu Ala Leu Leu Ile Leu Cys Val Ile Tyr	
180 185 190	
tgt aag aga cag ttt atg gag aag aaa ccc agc tgg tct ctg cgg tca	624
Cys Lys Arg Gln Phe Met Glu Lys Lys Pro Ser Trp Ser Leu Arg Ser	
195 200 205	
cag gac att cag tac aac ggc tct gag ctg tcg tgt ttt gac aga cct	672
Gln Asp Ile Gln Tyr Asn Gly Ser Glu Leu Ser Cys Phe Asp Arg Pro	
210 215 220	
cag ctc cac gaa tat gcc cac aga gcc tgc tgc cag tgc cgc cgt gac	720
Gln Leu His Glu Tyr Ala His Arg Ala Cys Cys Gln Cys Arg Arg Asp	
225 230 235 240	
tca gtg cag acc tgc ggg ccg gtg cgc ttg ctc cca tcc atg tgc tgt	768
Ser Val Gln Thr Cys Gly Pro Val Arg Leu Leu Pro Ser Met Cys Cys	
245 250 255	
gag gag gcc tgc agc ccc aac ccg gcg act ctt ggt tgt ggg gtg cat	816
Glu Glu Ala Cys Ser Pro Asn Pro Ala Thr Leu Gly Cys Gly Val His	
260 265 270	
tct gca gcc agt ctt cag gca aga aac gca ggc cca gcc ggg gag atg	864
Ser Ala Ala Ser Leu Gln Ala Arg Asn Ala Gly Pro Ala Gly Glu Met	
275 280 285	
gtg ccg act ttc ttc gga tcc ctc acg cag tcc atc tgt ggc gag ttt	912
Val Pro Thr Phe Phe Gly Ser Leu Thr Gln Ser Ile Cys Gly Glu Phe	

```

290                295                300
tca gat gcc tgg cct ctg atg cag aat ccc atg ggt ggt gac aac atc 960
Ser Asp Ala Trp Pro Leu Met Gln Asn Pro Met Gly Gly Asp Asn Ile
305                310                315                320

tct ttt tgt gac tct tat cct gaa ctc act gga gaa gac att cat tct 1008
Ser Phe Cys Asp Ser Tyr Pro Glu Leu Thr Gly Glu Asp Ile His Ser
325                330                335

ctc aat cca gaa ctt gaa agc tca acg tct ttg gat tca aat agc agt 1056
Leu Asn Pro Glu Leu Glu Ser Ser Thr Ser Leu Asp Ser Asn Ser Ser
340                345                350

caa gat ttg gtt ggt ggg gct gtt cca gtc cag tct cat tct gaa aac 1104
Gln Asp Leu Val Gly Gly Ala Val Pro Val Gln Ser His Ser Glu Asn
355                360                365

ttt aca gca gct act gat tta tct aga tat aac aac aca ctg gta gaa 1152
Phe Thr Ala Ala Thr Asp Leu Ser Arg Tyr Asn Asn Thr Leu Val Glu
370                375                380

tca gca tca act cag gat gca cta act atg aga agc cag cta gat cag 1200
Ser Ala Ser Thr Gln Asp Ala Leu Thr Met Arg Ser Gln Leu Asp Gln
385                390                395                400

gag agt ggt gct gtc atc cac cca gcc act cag acg tcc ctc cag gaa 1248
Glu Ser Gly Ala Val Ile His Pro Ala Thr Gln Thr Ser Leu Gln Glu
405                410                415

gct taa agaacctgct tctttctgca gtagaagcgt gtgctggaac ccaaagagta 1304
Ala *

ctccttttgtt aggettattgg actgagcagt ctggaccttg catggcttct ggggcaaaaa 1364
taaattctgaa ccaaactgac ggcatttgaa gcctttcagc cagttgcttc tgagccagac 1424
cagctgtaag ctgaaacctc aatgaataac aagaaaagac tccaggccga ctcatgatac 1484
tctgcatctt tctacatga gaagcttctc tgccacaaaa gtgacttcaa agacggatgg 1544
gttgagctgg cagcctatga gattgtggac atataacaag aaacagaaat gccctcatgc 1604
ttattttcat ggtgattgtg gttttacaag actgaagacc cagagtatac tttttc 1660

<210> 4
<211> 417
<212> PRT
<213> Homo sapiens

<220>
<221> VARIANT
<222> 31
<223> Polymorphic amino acid Ser or Thr

<221> VARIANT
<222> 221
<223> Polymorphic amino acid Phe or Leu

<221> VARIANT
<222> 223
<223> Polymorphic amino acid Arg or Pro

<221> VARIANT
<222> 330
<223> Polymorphic amino acid Pro or Arg

```

Inte ional Application No
PCT/IB 02/03344

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K G01N A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, SEQUENCE SEARCH

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 51645 A (GENSET SA ;YEN POTIN FRANCES (US); BIHAIN BERNARD (US); FRUEBIS JO) 19 July 2001 (2001-07-19) page 58, line 11 -page 59, line 15 claims ---	1-6
X	EP 1 033 134 A (OTSUKA PHARMA CO LTD) 6 September 2000 (2000-09-06) page 2, line 23 - line 26 claims ---	1-6
X	WO 00 68380 A (INCYTE GENOMICS INC ;AZIMZAI YALDA (US); YUE HENRY (US); BANDMAN O) 16 November 2000 (2000-11-16) SEQ ID N°8 page 35, line 17 -page 37, line 5 claims ---	1-6

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

21 January 2003

Date of mailing of the international search report

29/01/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer _____

Didelon, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/03344

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 59618 A (SMITHKLINE BEECHAM CORP) 25 November 1999 (1999-11-25) SEQ ID N°2 page 1, line 23 - line 32 page 3, line 1 - line 12 page 15, line 17 - line 20 ----	1-6
X	WO 00 73448 A (ZYMOGENETICS INC) 7 December 2000 (2000-12-07) page 72, line 28 -page 73, line 33 page 86, line 21 -page 87, line 30 claims ----	1-6
X	WO 99 11791 A (UNIV WASHINGTON) 11 March 1999 (1999-03-11) page 22, line 1 -page 26, line 20 page 84, line 31 - line 32 page 86, line 18 ----	1-6
X	WO 01 38526 A (GLAXO GROUP LTD ;KITSON JEREMY DAVID ALISTAIR (GB)) 31 May 2001 (2001-05-31) claim 13 page 14, line 25 -page 15, line 9 -----	1-6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/03344

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0151645	A	19-07-2001	AU 5789901 A	24-07-2001
			BR 0107626 A	15-10-2002
			EP 1248849 A1	16-10-2002
			WO 0151645 A1	19-07-2001
			US 2002058617 A1	16-05-2002
			US 2002037849 A1	28-03-2002
			US 2002091080 A1	11-07-2002
EP 1033134	A	06-09-2000	EP 1033134 A1	06-09-2000
			US 6461821 B1	08-10-2002
			WO 9921577 A1	06-05-1999
WO 0068380	A	16-11-2000	AU 5129800 A	21-11-2000
			EP 1177296 A2	06-02-2002
			WO 0068380 A2	16-11-2000
WO 9959618	A	25-11-1999	EP 1085897 A1	28-03-2001
			EP 1083923 A1	21-03-2001
			JP 2002515452 T	28-05-2002
			WO 9959618 A1	25-11-1999
			WO 9959619 A1	25-11-1999
			US 2001009905 A1	26-07-2001
WO 0073448	A	07-12-2000	AU 5159500 A	18-12-2000
			EP 1185645 A1	13-03-2002
			WO 0073448 A1	07-12-2000
WO 9911791	A	11-03-1999	AU 9376498 A	22-03-1999
			WO 9911791 A2	11-03-1999
WO 0138526	A	31-05-2001	AU 1531901 A	04-06-2001
			WO 0138526 A1	31-05-2001